Pharmacotherapy of hypercholesterolaemia: statins in clinical practice

Bibliography

• TINT GS, IRONS M, ELIAS ER et al.: Defective cholesterol biosynthesis associated with the Smith-Lemli-Optiz syndrome. N Engl. J. Med. (1994) 330:107–113.
   PubMed Web of Science ®Google Scholar
• •This is an original report on defective cholesterol biosyn-thesis in Smith-Lemli-Optiz syndrome.
   Google Scholar
• LACOSTE L, LAM JYT, HUNG J, LETCHACOVSKI G, SOLYMOSS C, WATERS D: Hyperlipidemia and coronary disease. Circulation (1995) 92: 3172–3177.
   PubMedGoogle Scholar
• Heart and stroke in Canada. In: Heart and Stroke Founda-tion of Canada (1997).
   Google Scholar
• SHEPHERD J, COBBE SM, FORD I et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med. (1995) 333:1301–1307.
   PubMed Web of Science ®Google Scholar
• ••A well-designed large-scale primary prevention trial.
   Google Scholar
• SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY GROUP: Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandi-navian Simvastatin Survival Study (45). Lancet (1994) 344:1383–1389.
   PubMed Web of Science ®Google Scholar
• ••A well-designed large-scale secondary prevention trial. Exp. Opin. Pharmacother. (2000) 1(4)
   Google Scholar
• MAAS INVESTIGATORS: Effect of simvastatin oncoronary atheroma: the Multicenter Anti-Atheroma Study (MAAS). Lancet (1994) 344:633–638.
   PubMed Web of Science ®Google Scholar
• PITT B, MANCINI GB, ELLIS SG, ROSMAN HS, PARK JS,MCGOVERN ME: Pravastatin limitation of Atheroscle-rosis in the Coronary Arteries (PIACI): reduction in atherosclerosis progression and clinical events. PLAC I investigation./ Am. Coll. Cardiol. (1995) 26:1133–11399.
   PubMed Web of Science ®Google Scholar
• •This study reports pravastatin effects on inhibition of progression of coronary atherosclerosis and reduction in MI.
   Google Scholar
• CROUSE JR 3RD, BYINGTON RP, BOND MG et al.: Pravas-tatin, lipids and atherosclerosis in the carotid arteries (PLACID. Am. J. Cardiol. (1995) 75:455–459.
   Google Scholar
• BYINGTON RP, JUKEMA JW, SALONEN JT et al.:Reduction in cardiovascular events during pravastatin therapy: pooled analysis of clinical events of the pravastatin atherosclerosis intervention program. Circulation (1995) 92:2419–2425.
   PubMed Web of Science ®Google Scholar
• SACKS FM, PFEFFER MA, MOYE LA et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N. Engl. J. Med. (1996) 335:1001–1009.
   Google Scholar
• ••A well-design large-scale secondary prevention trial.
   Google Scholar
• BLANKENHORN DH, AZEN SP, KRAMSCH DM et al.: Coronary angiographic changes with lovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS). The MARS research group. Ann. Intern. Med. (1993) 119:968–976.
   Web of Science ®Google Scholar
• BROWN G, ALBERS JJ, FISHER LD et al.: Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipo-protein B. N. Engl. J. Med. (1990) 323:1289–1298.
   PubMed Web of Science ®Google Scholar
• WATERS D, HIGGINSON L, GLADSTONE P et al.: Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative angiography: the Canadian Coronary Atherosclerosis Intervention Trial. Circulation (1994) 89:959–968.
   PubMed Web of Science ®Google Scholar
• •This study showed that lovastatin can significantly reduce progression of atherosclerotic lesions.
   Google Scholar
• FROHLICH J, FODOR G, MCPHERSON R, GENEST J, LANGNER N: Rationale for and outline of the recommendations of the working group on hypercho-lesterolemia and other dyslipidemias: interim report. Dyslipidemia working group of Health Canada. Can. J. Cardiol. (1998) 14(Suppl. A):17A–21A.
   Google Scholar
• •Canadian Guidelines on management of hypercholesterolaemia.
   Google Scholar
• NATIONAL CHOLESTEROL EDUCATION PROGRAM: Second report of the expert panel on detection, evalua-tion and treatment of high blood cholesterol in adults (adult treatment panel II). Circulation (1994) 89:1329–1445.
   Web of Science ®Google Scholar
• •American Guidelines on management of hypercholesterolaemia.
   Google Scholar
• BUCHER HC, GRIFFITH LE, GUYATT GH: Systemic review on the risk and benefit of different cholesterol- lowering interventions. Arterioscler. Thromb. Vasc. Biol. (1999) 19:187–195.
   PubMed Web of Science ®Google Scholar
• ENDO A, KURODA M: Citrinin and inhibitor of choles-terol synthesis. J. Antibiotics (1976) 29: 841–843.
   PubMed Web of Science ®Google Scholar
• •Original report on discovery of HMG-CoA reductase inhibitors.
   Google Scholar
• DUGGAN DE, VICKERS S: Physiological disposition ofHMG-CoA reductase inhibitors. Drug Metab. Rev. (1990) 22:333–362.
   PubMed Web of Science ®Google Scholar
• GERMERSHAUSEN JI, HUNT VM, BOSTEDOR RG, BAILEYPJ, KARKAS JD, ALBERTS AW: Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivo. Biochem. Biophys. Res. Commun. (1989) 158:667–675.
   PubMed Web of Science ®Google Scholar
• AMERICAN MEDICAL ASSOCIATION: Drug evaluations.(1995):2486.
   Google Scholar
• MERCK: MevacorT' Package Insert. West Point, PA, USA(1992).
   Google Scholar
• RICHTER WO, JACOB BG, SCHWANDT P: Interaction between fiber and lovastatin. Lancet (1991) 338:706.
   PubMed Web of Science ®Google Scholar
• MERCK: ZocorT'Package Insert. West Point, PA, USA (1993).
   Google Scholar
• PAN H, DEVAULT A, GLAESS S et al.: Effects of food on the pharrnacokinetics of pravastatin, an HMG-CoA reductase inhibitor. Arteriosclerosis (1988) 8:588a
   Google Scholar
• SMITH HT, JOKUBAITIS LA, TROENDLE AJ, HWANG DS,ROBINSON WT: Pharmacokinetics of fluvastatin and specific drug interactions. Am. J. Hypertens. (1993) 6:375S–382S.
   Google Scholar
• RADULOVIC LL, GILLA DD, POSVAR EL, SEDMAN AJ, WHITFIELD LR: Effect of food on the bioavailability of atorvastatin, an HMG-CoA reductase inhibitor. J. Clin. Pharmacol. (1995) 35:990–994.
   PubMed Web of Science ®Google Scholar
• ENDO A, KURODA M, TANAZAWA K: Competitive inhibition of 3-hydroxy-3-methylglutarykoenzyme A reductase by ML-236A and ML-236B, fungal metabo-lites having hypocholesterolemic activity. FESS Lett. (1976) 72:323–326.
   PubMed Web of Science ®Google Scholar
• CORSINI A, MAGGI FM, CATAPANO AL: Pharmacology ofcompetitive inhibitors of HMG-CoA reductase. Pharmacol. Res. (1995) 31:9–27.
   PubMed Web of Science ®Google Scholar
• BISCHOFF H, ANGERBAUER R, BENDER J et al.: Cerivas-tatin: pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor. Atherosclerosis (1997) 135:119–130.
   PubMed Web of Science ®Google Scholar
• JONES P, KAFONEK S, LAURORA I, HUNNINGHAKE D: Comparative dose efficacy study of atorvastatin versus simvastatin, paravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am. J. Cardiol. (1998) 81:582–587.
   PubMed Web of Science ®Google Scholar
• •A good comparison study on the efficacy of statins.
   Google Scholar
• STEIN E, SPRECHER D, ALLENBY KS, TOSIELLO RL, WHALEN E, RIPA SR: Cerivastatin, a new potent synthetic HMG-CoA reductase inhibitor: effect of 0.2 mg daily in subjects with primary hypercholestero-lemia. J. Cardiovasc. Pharmacol. Ther. (1997) 2:7-16. Exp. Opin. Pharmacother. (2000) 1(4) © Ashley Publications Ltd. All rights reserved.
   Google Scholar
• BRADFORD RH, SHEAR CL, CHREMOS AN et al.: Expanded clinical evaluation of lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipopro-teins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch. Intern. Med. (1991) 151:43–49.
   Google Scholar
• ••A good report on efficacy and safety of lovastatin.
   Google Scholar
• TSUJITIA Y, KURODA M, SHIMADA Y et al.: CS-514, acompetitive inhibitor of 3 -hydroxy-3-methylglutarykoenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species. Biochim. Biophys. Acta (1986) 877:50–60.
   PubMedGoogle Scholar
• YAMAUCHI S, LINSCHEER WG, BEACH DH: Increase inserum and bile cholesterol and HMG-CoA reductase by lovastatin in rats. Am. J. Physiol. (1991) 260:G625–G630.
   Google Scholar
• ENDO A, TSUJITA Y, KURODA M, TANAZAWA K: Effectsof M236B on cholesterol metabolism in mice and rats: lack of hypocholesterolemic activity in normal animals. Biochim. Biophys. Acta (1979) 575:266–276.
   PubMed Web of Science ®Google Scholar
• ROSENSON RS, TANGNEY CC: Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA (1998) 279:1643–1650.
   PubMed Web of Science ®Google Scholar
• ALFON J, GUASCH JF, BERROZPE M, BADIMON L: Nitricoxide synthase II (NOS II) gene expression correlates with atherosclerotic intimal thickening. Preventive effects of HMG-CoAreductase inhibitors. Atherosclerosis (1999) 145:325–331.
   PubMed Web of Science ®Google Scholar
• LAAKSONEN R, JOKELAINEN K, LAAKSO J et al.: Theeffects of sirnivastatin treatment on natural antioxi-dants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. Am. J. Cardiol. (1996) 77:851–854.
   PubMed Web of Science ®Google Scholar
• RAAL FJ, PILCHER GJ, YELLER MG, KOTZE MJ, JOFFE BI:Efficacy of vitamin E compared with either simvastatin or atorvastatin in preventing the progression of atherosclerosis in homozygous familial hypercholes-terolemia. Am. J. Cardiol. (1999) 84:1344–1346.
   PubMed Web of Science ®Google Scholar
• FAGGIOTTO A, PAOLETTI R: Sate-of-art lecture. Statinsand blockers of the renin-angiotensin system: vascular protection beyond their primary mode of action. Hypertension (1999) 34:987–996.
   Google Scholar
• ROGERS MJ: Statins: lower lipids and better bones?Nature Med. (2000) 6:21–23.
   Google Scholar
• GLORIOSO N, TROFFA C, FILIGHEDDU F et al.: Effect ofthe HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension (1999) 34:1281–1286.
   PubMed Web of Science ®Google Scholar
• DAVIGNON J, LAAKSONEN R: Low-density lipoprotein-independent effects of statins. Curr.Opin. Lipidol.(1999) 10:543–559.
   PubMed Web of Science ®Google Scholar
• LIPID STUDY GROUP: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The long-term intervention with pravastatin in ischemic disease (LIPID) study group. N. Engl. J. Med. (1998) 339:1349–1357.
   Google Scholar
• ••The largest secondary prevention trial.
   Google Scholar
• FURBERG CD, ADAMS HP JR, APPLEGATE WB et al.: Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) research group. Circulation (1994) 90:1679–1687.
   PubMed Web of Science ®Google Scholar
• HERD JA, BALLANTYNE CM, FARMER JA et al.: Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and coronary Atherosclerosis Study [LCAS]). Am. J. Cardiol. (1997) 80:278–286.
   PubMed Web of Science ®Google Scholar
• BALLANTYNE CM, HERD JA, FERLIC LL et al.: Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy. Circulation (1999) 99:736–743.
   PubMed Web of Science ®Google Scholar
• DOWNS JR, CLEARFIELD M, WETS S et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JANIA (1998) 279:1615–1622.
   Google Scholar
• ••One of the largest primary prevention trials.
   Google Scholar
• SALONEN R, NYYSSONEN K, PORKKALA E et al.: Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary prevention trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation (1995) 92:1758–1764.
   Google Scholar
• FOLEY DP, BONNIER H, JACKSON G et al.: Prevention of restenosis after coronary balloon angioplasy: retionak and design of the Fluvastatin Angioplasty Restenosis (FLARE) trial. The FLARE study group. Am.J. Cardiol. (1994) 73:50D–61D.
   Google Scholar
• •A well-designed trial on prevention of restenosis by statins.
   Google Scholar
• SERRUYS PW, FOLEY DP, JACKSON G et al.: A random-ized placebo-controlled trial of fluvastatin for preven-tion of restenosis after successful coronary ballon angioplasty, final results of the Fluvastatin Angiographic Restenosis (FLARE) trial. Eur. Heart J. (1999) 20:58–69.
   PubMed Web of Science ®Google Scholar
• STEIN E: Cerivastatin in primary hyperlipidemia- amulticenter analysis of efficacy and safety. Atheroscle-rosis (1998) 139\(Suppl. 1):S15–22.
   Google Scholar
• GUERIN M, LASSEL TS, LE GOFF W, FARNIER M, CHAPMAN MJ: Action of atorvastatin in combined hyperlipidemia: preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler. Thromb. Vasc. Biol.(2000) 20:189–197.
   PubMed Web of Science ®Google Scholar
• MARAIS GE, LARSON KK: Rhabdomyolysis and acute renal failure induced by combination lovastatin and gemfibrozil therapy. Ann. Intern. Med. (1990) 112:228-230. Exp. Opin. Pharmacother. (2000) 1(4) © Ashley Publications Ltd. All rights reserved.
   Google Scholar
• PIERCE LR, WYSOWSKI DK, GROSS TP: Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA (1990) 264:71–75.
   PubMed Web of Science ®Google Scholar
• GARNETTW R :Interactionswithhydroxymethyglutaryl-coenzyme A reductase inhibi-tors. Am. J. Health-Syst. Pharm. (1995) 52:1639–1645.
   PubMedGoogle Scholar
• SMIT JW, JANSEN GH, DE BRUIN TW, ERKELENS DW: Treatment of combined hyperlipidemia with fluvas-tatin and gemfibrozil, alone or in combination, does not induce muscle damage. Am. J. Cardiol. (1995) 76:126A–128A.
   Google Scholar
• MURATTI EN, PETERS TK, LEITERSDORF E: Fluvastatin infamilial hypercholesterolemia: a cohort analysis of the response to combination treatment. Am. J. Cardiol. (1994) 73:30D–38D.
   Google Scholar
• SPENCE JD, MUNOZ CE, HENDRICKS L, LATCHINIAN L,KHOURI HE: Pharmacokinetics of the combination of fluvastatin and gemfibrozil. Am. J. Cardiol. (1995) 76:80A–83A.
   Google Scholar
• DUELL PB, CONNOR WE, ILLINGWORTH DR: Rhabdomy-olysis after taking atorvastatin with gemfibrozil. Am.J. Cardiol. (1998) 81:368–369.
   PubMed Web of Science ®Google Scholar
• REAVEN P, WITZTUM JL: Lovastatin, nicotonic acid andrhabdomyolysis. Ann. Intern. Med. (1988) 109:597–598.
   PubMed Web of Science ®Google Scholar
• ILLINGWORTH DR: Management of hyperlipidemia: goals for the prevention of atherosclerosis. Clin. Invest. Med. (1990) 13:211–218.
   PubMed Web of Science ®Google Scholar
• BRISTOL-MYERS SQUIBB: PravachoIT' Package Insert.Princeton, NJ, USA (1993).
   Google Scholar
• MUCK W, RITTER W, FREY R, WETZELSBERGER N, LUCKER PW, KUHLMANN J: Influence of cholesty-ramine on the pharmacokinetics of cerivastatin. Clin. Pharmacol. Ther. (1997) 35:250–254.
   Web of Science ®Google Scholar
• CORSINI A, BELLOSTA S, BAETTA R, FUMAGALLI R, PAOLETTI R, BERNINI F: New insights into the pharma-codynamic and pharmacokinetic properties of statins. Pharmacol. Ther. (1999) 84:413–428.
   PubMed Web of Science ®Google Scholar
• AHMAD S: Lovastatin:warfarin interaction. Arch. Intern.Med. (1990) 150:2404.
   Google Scholar
• STERN R, ABEL R, GIBSON GL, BESSERER J: Atorvastatin does not alter the anticoagulant activity of warfarin. J. Clin. Pharmacol. (1997) 37:1062–1064.
   PubMed Web of Science ®Google Scholar
• PAN HY, TRISCARI J, DEVAULT AR et al.: Pharmacoki-netic interaction between propranolol and the HMG-CoA reductase inhibitors pravastatin and lovastatin. Br. J. Clin. Pharmacol. (1991) 31:665–670.
   PubMed Web of Science ®Google Scholar
• Compendium of Pharmaceuticals and Specialties. (30th Edition). (1995):2483–2487.
   Google Scholar
• TO BERT JA: Rhabdomyolysis in patient receivinglovastatin after cardiac transplentation. N Engl.J. Med. (1988) 318:48.
   PubMedGoogle Scholar
• LI PK, MAK TW, WANG AY et al.: The interaction offluvastatin and cyclosporine A in renal transplant patients. Int. J. Clin. Pharmacol. Ther. (1995) 33:246–248.
   PubMed Web of Science ®Google Scholar
• SANDOZ PHARMACEUTICALS: LescolTm Package Insert. East Hanover, NJ, USA (1994).
   Google Scholar
• MUCK W, RITTER W, DIETRICH H, FREY R, KUHLMANN J: Influence of the antacids Maalox and the H2-antag-onist cimetidine on the pharmacokinetics of cerivas-tatin. Intl. J. Clin. Pharmacol. Ther. (1997) 35:261–264.
   PubMed Web of Science ®Google Scholar
• MEYER BH, SCHOLTZ HE, MULLER FO et al.: Lack of interaction between ramipril and simvastatin. Eur. J. Pharmacol. (1994) 47:373–375.
   Web of Science ®Google Scholar
• LEES RS: Rhabdomyolysis from the co-administration of lovastatin and the antifungal agent itraconazole. N Engl. J. Med. (1995) 333:664–665.
   PubMed Web of Science ®Google Scholar
• APPEL S, RUFENACHT T, KALAFSKY G et al.: Lack of interaction between fluvastatin and oral hypogly-cemic agents in healthy subjects and in patients with non-insulin-dependent diabetes mellitus. Am. J. Cardiol. (1995) 76:29A–32A.
   Google Scholar
• MUCK W, MAI I, FRITSCHE L et al.: Increase in cerivas-tatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients. Clin. Pharmacol. Ther. (1999) 65:251–261.
   PubMed Web of Science ®Google Scholar
• MALTZ HC, BALOG DL, CHEIGH JS: Rabdomyolysis associated with concomitant use of atorvastatin and cyclosporine. Ann. Pharmacother. (1999) 33:1176–79.
   PubMed Web of Science ®Google Scholar
• FROHLICH J: When not to use HMG-CoA reductase inhibitors. Can. J. Cardiol. (1992) 8:41A–42A.
   Google Scholar
• •A good summary on contraindications for the use of statins.
   Google Scholar
• DUCOBU J, BRASSEUR D, CHAUDRON JM et al.: Simvas-tatin use in children. Lancet (1992) 339:1488.
   PubMed Web of Science ®Google Scholar
• SINZINGER H, SCHMID P, PIRICH C et al.: Treatment ofhypercholesterolemia in children. Lancet (1992) 340:548–549.
   PubMed Web of Science ®Google Scholar
• BLACK DM, BAKKER-ARKEMA RG, NAWROCKI JW: Anoverview of the clinical safety profile of atorvastatin (lipitor), a new HMG-CoA reductase inhibitor. Arch. Intern. Med. (1998) 158:577–584.
   PubMed Web of Science ®Google Scholar
• WOLFFENBUTTEL BH, MAHLA G, MULLER D, PENTRUP A, BLACK DM: Efficacy and safety of a new cholesterol synthesis inhibitor, atorvastatin, in comparison with simvastatin and pravastatin, in subjects with hypercholesterolemia. Neth. J. Med. (1998) 52:131–138.
   PubMed Web of Science ®Google Scholar
• JEPPESEN U, GAIST D, SMITH T, SINDRUP SH: Statins and peripheral neuropathy. Eur. J. Clin. Pharmacol. (1999) 54:835–838.
   PubMed Web of Science ®Google Scholar
• POSSAMAI G, BOVO P, SANTONASTASO M: Therombo-cytopenic purpura during therapy with simvastatin. Haematologica (1992) 77:357–358.
   PubMedGoogle Scholar
• MCCARTHY 41, PORCU P, FAUSEL CA, SWEENEY CJ, DANIELSON CF: Thrombocytopenic purpura and simvastatin. Lancet (1998) 352:1284–1285.
   PubMed Web of Science ®Google Scholar
• KHOSLA R, BUTMAN AN, HAMMER DF: Simvastatin-induced lupus erythematosus. South Med. J. (1998) 91:873–874.
   PubMed Web of Science ®Google Scholar
• DE PINIEUX G, CHARIOT P, AMMI-SAID M et al.: Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. Br. J. Clin. Pharmacol. (1996) 42:333–337.
   PubMed Web of Science ®Google Scholar
• KOREN MJ, SMITH DG, HUNNINGHAKE DB et al.: The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolemic patients. A comparison of atorvastatin, simvastatin, lovastatin and fluvastatin. Pharmacoeconomics (1998) 14:59–70.
   Google Scholar
• CARO J, KLITTICH W, MCGUIRE A et al.: The west of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravas-tatin. Br. Med. J. (1997) 315:1577–1582.
   PubMedGoogle Scholar
• FARMER JA: Economic implications of lipid-lowering trials: current considerations in selecting a statin. Am. J. Cardiol. (1998) 82:26M–31M.
   Google Scholar
• SUPERKO HR: Cost-effective treatment of coronary artery disease- the new imperative. Clin. Cardiol. (1996) 19:650–655.
   PubMed Web of Science ®Google Scholar
• MOGHADASIAN MH: Clinical pharmacology of 3-hydrox-3-methylglutaryl coenzyme A reductase inhibitors. Life Sci. (1999) 65:1329–1337.
   PubMed Web of Science ®Google Scholar
• •A detailed review on clinical pharmacology of statins.
   Google Scholar
• HOLMES CL, SCHULZER M, MANCINI GBJ: Angiographic results of lipid-lowering trials: a systemic review and meta-analysis. In: Cholesterol-Lowering Therapy: Evaluation of Clinical Trial Evidence. SM Grundy (Ed.), Marcel Dekker, Inc., New York, USA (2000):191–219.
   Google Scholar
• •A comprehensive review and meta-analysis of the clinical outcome of lipid-lowering trials.
   Google Scholar
• BROWN AS, BAKKER-ARKEMA RG, YELLEN L et al.: Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin. J. Am. Coll. Cardiol. (1998) 32:665–672.
   PubMed Web of Science ®Google Scholar
• •This study compares several statins in achieving NCEP goals.
   Google Scholar
• SUPERKO HR, KRAUSS RM: Coronary artery disease regression. Convincing evidence for the benefit of aggressive lipoprotein management. Circulation (1994) 90:1056–1069.
   Google Scholar
• MIETTINEN TA, GYLLING H: Basal non-cholesterol sterols reveal a subgroup of 4S not benefited by simvastatin-induced decrease of recurrent coronary events. Atherosclerosis (1997) 134:48.
   Web of Science ®Google Scholar